Indian court locks dasatinib generic amid "bald" defence
This article was originally published in Scrip
Executive Summary
An Indian court has maintained a restraining order against certain BDR group firms in a patent infringement case concerning Bristol- Myers Squibb's anticancer, Sprycel (dasatinib), though it appears to have left the door somewhat ajar on whether or not the monohydrate form of the compound is covered in the suit patent.